AllTrials has called upon the US Food and Drug Administration (FDA) to impose fines up to $10,000 a day against clinical trial sponsors that fail to publish trial results on ClinicalTrials.gov.

The call was made through an open letter written by Ben Goldacre and Síle Lane on behalf of AllTrials to FDA commissioner Dr Scott Gottlieb.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Goldacre and Síle Lane wrote in the letter: “As the body responsible for compliance with the FDA Amendments Act 2007, you have the power to sanction those who break this law.”

According to AllTrials, FDA has not issued a single fine to the trials whose results are pending for years.

They further added: “Since 2014, AllTrials has been asking the FDA to censure these sponsors.

“The FDA has assured us, publicly and privately, that new clarifying rules, the FDAAA Final Rule, will help you do so.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Relevant trials have 13 months from completion (12 + 1 for quality check) to post summary results and adverse event information.”

“Relevant trials have 13 months from completion (12 + 1 for quality check) to post summary results and adverse event information.”

In order to help identify missing trial results, AllTrials has launched a new tracking tool to publicly flag sponsors and trials that violate their reporting deadline.

The tool became live on Monday and will list the trials, which are subject to FDAAA 2007and crossed their specified deadlines for publishing results, using ClinicalTrials.gov’s data.

A ranking of the sponsors will also be highlighted on the tool with the most trials that appear in the data to be in violation of the law.

The tool will also display an estimate of the total amount of fines that the FDA could impose on violators.